{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T16:32:00Z","timestamp":1785342720831,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T00:00:00Z","timestamp":1732838400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-81642-1","type":"journal-article","created":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T10:00:52Z","timestamp":1732874452000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Identification of ETV5 as a prognostic marker related to epigenetic modification in pan-cancer and facilitates tumor progression in hepatocellular carcinoma"],"prefix":"10.1038","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3175-4097","authenticated-orcid":false,"given":"Hongmeng","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luyu","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianle","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhao","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2783-7850","authenticated-orcid":false,"given":"Hong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,29]]},"reference":[{"key":"81642_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global Cancer statistics 2020: GLOBOCAN estimates of incidence and Mortality Worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"81642_CR2","doi-asserted-by":"publisher","first-page":"6497","DOI":"10.1245\/s10434-022-12151-6","volume":"29","author":"SVS Deo","year":"2022","unstructured":"Deo, S. V. S., Sharma, J. & Kumar, S. GLOBOCAN 2020 report on global cancer burden: Challenges and opportunities for surgical oncologists. Ann. Surg. Oncol. 29, 6497\u20136500 (2022).","journal-title":"Ann. Surg. Oncol."},{"key":"81642_CR3","doi-asserted-by":"publisher","first-page":"101948","DOI":"10.1016\/j.ctrv.2019.101948","volume":"83","author":"G Bregni","year":"2020","unstructured":"Bregni, G. et al. Adjuvant chemotherapy for rectal cancer: current evidence and recommendations for clinical practice. Cancer Treat. Rev. 83, 101948 (2020).","journal-title":"Cancer Treat. Rev."},{"key":"81642_CR4","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1038\/s41392-021-00648-7","volume":"6","author":"R Huang","year":"2021","unstructured":"Huang, R. & Zhou, P. K. DNA damage repair: Historical perspectives, mechanistic pathways and clinical translation for targeted cancer therapy. Signal Transduct. Target. Ther. 6, 254 (2021).","journal-title":"Signal Transduct. Target. Ther."},{"key":"81642_CR5","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1038\/s41573-018-0007-y","volume":"18","author":"J Galon","year":"2019","unstructured":"Galon, J. & Bruni, D. Approaches to treat immune hot, altered and cold tumours with combination immunotherapies. Nat. Rev. Drug Discov 18, 197\u2013218 (2019).","journal-title":"Nat. Rev. Drug Discov"},{"key":"81642_CR6","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1053\/j.gastro.2023.02.005","volume":"164","author":"C Zhou","year":"2023","unstructured":"Zhou, C. et al. Disruption of SLFN11 Deficiency-Induced CCL2 signaling and macrophage M2 polarization potentiates Anti-PD-1 therapy efficacy in Hepatocellular Carcinoma. Gastroenterology 164, 1261\u20131278 (2023).","journal-title":"Gastroenterology"},{"key":"81642_CR7","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1038\/s41392-020-00300-w","volume":"5","author":"H Song","year":"2020","unstructured":"Song, H. et al. Epitranscriptomics and epiproteomics in cancer drug resistance: Therapeutic implications. Signal. Transduct. Target. Ther. 5, 193 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"81642_CR8","doi-asserted-by":"publisher","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","volume":"121","author":"RA Ward","year":"2021","unstructured":"Ward, R. A. et al. Challenges and opportunities in cancer drug resistance. Chem. Rev. 121, 3297\u20133351 (2021).","journal-title":"Chem. Rev."},{"key":"81642_CR9","doi-asserted-by":"crossref","unstructured":"Bezu, L., Chuang, A. W., Liu, P., Kroemer, G. & Kepp, O. Immunological effects of epigenetic modifiers. Cancers (Basel) 11, 1911 (2019).","DOI":"10.3390\/cancers11121911"},{"key":"81642_CR10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","volume":"28","author":"K Nepali","year":"2021","unstructured":"Nepali, K. & Liou, J. P. Recent developments in epigenetic cancer therapeutics: Clinical advancement and emerging trends. J. Biomed. Sci. 28, 27 (2021).","journal-title":"J. Biomed. Sci."},{"key":"81642_CR11","doi-asserted-by":"crossref","unstructured":"Martinez-Useros, J., Martin-Galan, M., Florez-Cespedes, M. & Garcia-Foncillas, J. Epigenetics of most aggressive solid tumors: Pathways, targets and treatments. Cancers (Basel) 13, 3209 (2021).","DOI":"10.3390\/cancers13133209"},{"key":"81642_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.molcel.2018.06.040","volume":"71","author":"GJ Sandoval","year":"2018","unstructured":"Sandoval, G. J. et al. Binding of TMPRSS2-ERG to BAF chromatin remodeling complexes mediates prostate oncogenesis. Mol. Cell. 71, 554\u2013566e557 (2018).","journal-title":"Mol. Cell."},{"key":"81642_CR13","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41419-022-04563-9","volume":"13","author":"C Zheng","year":"2022","unstructured":"Zheng, C., Liu, M., Ge, Y., Qian, Y. & Fan, H. HBx increases chromatin accessibility and ETV4 expression to regulate dishevelled-2 and promote HCC progression. Cell Death Dis. 13, 116 (2022).","journal-title":"Cell Death Dis."},{"key":"81642_CR14","doi-asserted-by":"publisher","first-page":"149137","DOI":"10.1016\/j.bbrc.2023.149137","volume":"684","author":"H Su","year":"2023","unstructured":"Su, H. et al. ETV4 facilitates angiogenesis in hepatocellular carcinoma by upregulating MMP14 expression. Biochem. Biophys. Res. Commun. 684, 149137 (2023).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"81642_CR15","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41568-020-0290-x","volume":"20","author":"F Martinez-Jimenez","year":"2020","unstructured":"Martinez-Jimenez, F. et al. A compendium of mutational cancer driver genes. Nat. Rev. Cancer 20, 555\u2013572 (2020).","journal-title":"Nat. Rev. Cancer"},{"key":"81642_CR16","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1038\/s41419-021-03717-5","volume":"12","author":"Y Peng","year":"2021","unstructured":"Peng, Y. et al. The role of E26 transformation-specific variant transcription factor 5 in colorectal cancer cell proliferation and cell cycle progression. Cell Death Dis. 12, 427 (2021).","journal-title":"Cell Death Dis."},{"key":"81642_CR17","doi-asserted-by":"crossref","unstructured":"DeSalvo, J. et al. ETV4 and ETV5 drive synovial sarcoma through cell cycle and DUX4 embryonic pathway control. J. Clin. Invest. 131, e141908 (2021).","DOI":"10.1172\/JCI141908"},{"key":"81642_CR18","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.1038\/s41598-017-00973-4","volume":"7","author":"M Arase","year":"2017","unstructured":"Arase, M. et al. Dynamics of chromatin accessibility during TGF-beta-induced EMT of ras-transformed mammary gland epithelial cells. Sci. Rep. 7, 1166 (2017).","journal-title":"Sci. Rep."},{"key":"81642_CR19","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1016\/j.neo.2018.09.003","volume":"20","author":"OR Puli","year":"2018","unstructured":"Puli, O. R. et al. The transcription factor ETV5 mediates BRAFV600E-Induced Proliferation and TWIST1 expression in papillary thyroid Cancer cells. Neoplasia 20, 1121\u20131134 (2018).","journal-title":"Neoplasia"},{"key":"81642_CR20","doi-asserted-by":"publisher","first-page":"6753","DOI":"10.1158\/0008-5472.CAN-06-4487","volume":"67","author":"M Monge","year":"2007","unstructured":"Monge, M. et al. ERM\/ETV5 up-regulation plays a role during myometrial infiltration through matrix metalloproteinase-2 activation in endometrial cancer. Cancer Res. 67, 6753\u20136759 (2007).","journal-title":"Cancer Res."},{"key":"81642_CR21","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1038\/s41598-019-57076-5","volume":"10","author":"LM Mus","year":"2020","unstructured":"Mus, L. M. et al. The ETS transcription factor ETV5 is a target of activated ALK in neuroblastoma contributing to increased tumour aggressiveness. Sci. Rep. 10, 218 (2020).","journal-title":"Sci. Rep."},{"key":"81642_CR22","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1007\/s10735-023-10148-3","volume":"54","author":"D Li","year":"2023","unstructured":"Li, D. et al. ETV5 transcriptionally activates TGFbeta1 and promotes cancer cell invasion and migration of NSCLC. J. Mol. Histol. 54, 419\u2013426 (2023).","journal-title":"J. Mol. Histol."},{"key":"81642_CR23","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1002\/ijc.32071","volume":"145","author":"X Cheng","year":"2019","unstructured":"Cheng, X. et al. ETS variant 5 promotes colorectal cancer angiogenesis by targeting platelet-derived growth factor BB. Int. J. Cancer 145, 179\u2013191 (2019).","journal-title":"Int. J. Cancer"},{"key":"81642_CR24","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1038\/s41419-020-03111-7","volume":"11","author":"H Feng","year":"2020","unstructured":"Feng, H. et al. Targeting tumor cell-derived CCL2 as a strategy to overcome Bevacizumab resistance in ETV5(+) colorectal cancer. Cell. Death Dis. 11, 916 (2020).","journal-title":"Cell. Death Dis."},{"key":"81642_CR25","doi-asserted-by":"publisher","first-page":"1305","DOI":"10.1111\/febs.14773","volume":"286","author":"SM Park","year":"2019","unstructured":"Park, S. M. et al. Systems analysis identifies potential target genes to overcome cetuximab resistance in colorectal cancer cells. FEBS J. 286, 1305\u20131318 (2019).","journal-title":"FEBS J."},{"key":"81642_CR26","doi-asserted-by":"publisher","first-page":"620811","DOI":"10.3389\/fphar.2020.620811","volume":"11","author":"AK Giri","year":"2020","unstructured":"Giri, A. K. Higher ETV5 expression associates with poor 5-Florouracil-based adjuvant therapy response in Colon cancer. Front. Pharmacol. 11, 620811 (2020).","journal-title":"Front. Pharmacol."},{"key":"81642_CR27","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7150\/ijbs.11218","volume":"11","author":"H Meng","year":"2015","unstructured":"Meng, H. et al. DNA methylation, its mediators and genome integrity. Int. J. Biol. Sci. 11, 604\u2013617 (2015).","journal-title":"Int. J. Biol. Sci."},{"key":"81642_CR28","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12943-018-0847-4","volume":"17","author":"S Wang","year":"2018","unstructured":"Wang, S., Chai, P., Jia, R. & Jia, R. Novel insights on m(6)a RNA methylation in tumorigenesis: A double-edged sword. Mol. Cancer 17, 101 (2018).","journal-title":"Mol. Cancer"},{"key":"81642_CR29","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1016\/j.omtn.2021.08.020","volume":"26","author":"G Guo","year":"2021","unstructured":"Guo, G. et al. Advances in mRNA 5-methylcytosine modifications: Detection, effectors, biological functions, and clinical relevance. Mol. Ther. Nucleic Acids. 26, 575\u2013593 (2021).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"81642_CR30","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/jhg.2013.66","volume":"58","author":"H Kimura","year":"2013","unstructured":"Kimura, H. Histone modifications for human epigenome analysis. J. Hum. Genet. 58, 439\u2013445 (2013).","journal-title":"J. Hum. Genet."},{"key":"81642_CR31","doi-asserted-by":"publisher","first-page":"4901","DOI":"10.1038\/onc.2014.453","volume":"34","author":"A Farria","year":"2015","unstructured":"Farria, A., Li, W. & Dent, S. Y. KATs in cancer: Functions and therapies. Oncogene 34, 4901\u20134913 (2015).","journal-title":"Oncogene"},{"key":"81642_CR32","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.jhep.2020.04.009","volume":"73","author":"Z Zhao","year":"2020","unstructured":"Zhao, Z. et al. Epitranscriptomics in liver disease: Basic concepts and therapeutic potential. J. Hepatol. 73, 664\u2013679 (2020).","journal-title":"J. Hepatol."},{"key":"81642_CR33","doi-asserted-by":"publisher","first-page":"D587","DOI":"10.1093\/nar\/gkac963","volume":"51","author":"M Kanehisa","year":"2023","unstructured":"Kanehisa, M., Furumichi, M., Sato, Y., Kawashima, M. & Ishiguro-Watanabe M. KEGG for taxonomy-based analysis of pathways and genomes. Nucleic Acids Res. 51, D587\u2013D592 (2023).","journal-title":"Nucleic Acids Res."},{"key":"81642_CR34","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1038\/nature11606","volume":"492","author":"MT McCabe","year":"2012","unstructured":"McCabe, M. T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations. Nature 492, 108\u2013112 (2012).","journal-title":"Nature"},{"key":"81642_CR35","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nrc.2017.20","volume":"17","author":"GM Sizemore","year":"2017","unstructured":"Sizemore, G. M., Pitarresi, J. R., Balakrishnan, S. & Ostrowski, M. C. The ETS family of oncogenic transcription factors in solid tumours. Nat. Rev. Cancer 17, 337\u2013351 (2017).","journal-title":"Nat. Rev. Cancer"},{"key":"81642_CR36","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.brainresbull.2016.02.010","volume":"121","author":"D Liu","year":"2016","unstructured":"Liu, D. et al. Brain-derived neurotrophic factor promotes vesicular glutamate transporter 3 expression and neurite outgrowth of dorsal root ganglion neurons through the activation of the transcription factors Etv4 and Etv5. Brain Res. Bull. 121, 215\u2013226 (2016).","journal-title":"Brain Res. Bull."},{"key":"81642_CR37","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1016\/j.devcel.2015.10.006","volume":"35","author":"JC Herriges","year":"2015","unstructured":"Herriges, J. C. et al. FGF-regulated ETV transcription factors control FGF-SHH feedback loop in lung branching. Dev. Cell 35, 322\u2013332 (2015).","journal-title":"Dev. Cell"},{"key":"81642_CR38","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/s12929-023-00909-3","volume":"30","author":"Y Wei","year":"2023","unstructured":"Wei, Y. et al. E26 transformation-specific transcription variant 5 in development and cancer: Modification, regulation and function. J. Biomed. Sci. 30, 17 (2023).","journal-title":"J. Biomed. Sci."},{"key":"81642_CR39","doi-asserted-by":"publisher","first-page":"3903","DOI":"10.1073\/pnas.1621177114","volume":"114","author":"Z Zhang","year":"2017","unstructured":"Zhang, Z. et al. Transcription factor Etv5 is essential for the maintenance of alveolar type II cells. Proc. Natl. Acad. Sci. U.S.A 114, 3903\u20133908 (2017).","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"key":"81642_CR40","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1038\/s41467-021-22941-3","volume":"12","author":"H Lin","year":"2021","unstructured":"Lin, H. et al. IP(6)-assisted CSN-COP1 competition regulates a CRL4-ETV5 proteolytic checkpoint to safeguard glucose-induced insulin secretion. Nat. Commun. 12, 2461 (2021).","journal-title":"Nat. Commun."},{"key":"81642_CR41","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1002\/hep.30594","volume":"70","author":"S Park","year":"2019","unstructured":"Park, S., Park, J., Kim, E. & Lee, Y. The capicua\/ETS translocation variant 5 axis regulates liver-resident memory CD8(+) T-cell development and the pathogenesis of liver Injury. Hepatology 70, 358\u2013371 (2019).","journal-title":"Hepatology"},{"key":"81642_CR42","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1186\/s13048-021-00899-6","volume":"14","author":"L Zhang","year":"2021","unstructured":"Zhang, L. et al. Biological and prognostic value of ETV5 in high-grade serous ovarian cancer. J. Ovarian Res. 14, 149 (2021).","journal-title":"J. Ovarian Res."},{"key":"81642_CR43","doi-asserted-by":"publisher","first-page":"7297","DOI":"10.1158\/1078-0432.CCR-04-0593","volume":"10","author":"A Chotteau-Lelievre","year":"2004","unstructured":"Chotteau-Lelievre, A. et al. Prognostic value of ERM gene expression in human primary breast cancers. Clin. Cancer Res. 10, 7297\u20137303 (2004).","journal-title":"Clin. Cancer Res."},{"key":"81642_CR44","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.7150\/ijms.71892","volume":"19","author":"MC Sun","year":"2022","unstructured":"Sun, M. C. et al. ETV5 overexpression promotes progression of esophageal squamous cell carcinoma by upregulating SKA1 and TRPV2. Int. J. Med. Sci. 19, 1072\u20131081 (2022).","journal-title":"Int. J. Med. Sci."},{"key":"81642_CR45","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.jaci.2013.12.021","volume":"134","author":"D Pham","year":"2014","unstructured":"Pham, D., Sehra, S., Sun, X. & Kaplan, M. H. The transcription factor Etv5 controls TH17 cell development and allergic airway inflammation. J. Allergy Clin. Immunol. 134, 204\u2013214 (2014).","journal-title":"J. Allergy Clin. Immunol."},{"key":"81642_CR46","doi-asserted-by":"publisher","first-page":"10062","DOI":"10.1074\/jbc.RA119.012130","volume":"295","author":"F Zhang","year":"2020","unstructured":"Zhang, F., Wang, S. & Zhu, J. ETS variant transcription factor 5 and c-Myc cooperate in derepressing the human telomerase gene promoter via composite ETS\/E-box motifs. J. Biol. Chem. 295, 10062\u201310075 (2020).","journal-title":"J. Biol. Chem."},{"key":"81642_CR47","doi-asserted-by":"publisher","first-page":"e2307242","DOI":"10.1002\/advs.202307242","volume":"11","author":"J Wen","year":"2024","unstructured":"Wen, J. et al. YTHDF2 is a therapeutic target for HCC by suppressing immune evasion and angiogenesis through ETV5\/PD-L1\/VEGFA axis. Adv. Sci. (Weinh) 11, e2307242 (2024).","journal-title":"Adv. Sci. (Weinh)"},{"key":"81642_CR48","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1186\/s12943-019-1053-8","volume":"18","author":"Y Chen","year":"2019","unstructured":"Chen, Y. et al. WTAP facilitates progression of hepatocellular carcinoma via m6A-HuR-dependent epigenetic silencing of ETS1. Mol. Cancer 18, 127 (2019).","journal-title":"Mol. Cancer"},{"key":"81642_CR49","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1038\/s41419-021-04228-z","volume":"12","author":"X Mao","year":"2021","unstructured":"Mao, X., Ji, T., Liu, A. & Weng, Y. ELK4-mediated lncRNA SNHG22 promotes gastric cancer progression through interacting with EZH2 and regulating miR-200c-3p\/Notch1 axis. Cell Death Dis. 12, 957 (2021).","journal-title":"Cell Death Dis."},{"key":"81642_CR50","doi-asserted-by":"publisher","first-page":"4345","DOI":"10.1038\/onc.2015.499","volume":"35","author":"MA Taylor","year":"2016","unstructured":"Taylor, M. A., Wappett, M., Delpuech, O., Brown, H. & Chresta, C. M. Enhanced MAPK signaling drives ETS1-mediated induction of miR-29b leading to downregulation of TET1 and changes in epigenetic modifications in a subset of lung SCC. Oncogene 35, 4345\u20134357 (2016).","journal-title":"Oncogene"},{"key":"81642_CR51","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.gpb.2020.02.002","volume":"18","author":"Z Li","year":"2020","unstructured":"Li, Z. et al. CRISPR screens identify essential cell growth mediators in BRAF inhibitor-resistant melanoma. Genom. Proteom. Bioinf. 18, 26\u201340 (2020).","journal-title":"Genom. Proteom. Bioinf."},{"key":"81642_CR52","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1158\/0008-5472.CAN-09-1577","volume":"70","author":"JR Dry","year":"2010","unstructured":"Dry, J. R. et al. Transcriptional pathway signatures predict MEK addiction and response to selumetinib (AZD6244). Cancer Res. 70, 2264\u20132273 (2010).","journal-title":"Cancer Res."},{"key":"81642_CR53","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1158\/1535-7163.MCT-18-0877","volume":"18","author":"JCM Uitdehaag","year":"2019","unstructured":"Uitdehaag, J. C. M. et al. Combined Cellular and biochemical profiling to identify predictive drug response biomarkers for kinase inhibitors approved for clinical use between 2013 and 2017. Mol. Cancer Ther. 18, 470\u2013481 (2019).","journal-title":"Mol. Cancer Ther."},{"key":"81642_CR54","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","volume":"7","author":"JM Llovet","year":"2021","unstructured":"Llovet, J. M. et al. Hepatocellular carcinoma. Nat. Rev. Dis. Prim. 7, 6 (2021).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"81642_CR55","doi-asserted-by":"publisher","first-page":"214","DOI":"10.2337\/db20-0619","volume":"70","author":"Z Mao","year":"2021","unstructured":"Mao, Z. et al. ETV5 regulates hepatic fatty acid metabolism through PPAR signaling pathway. Diabetes 70, 214\u2013226 (2021).","journal-title":"Diabetes"},{"key":"81642_CR56","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3892\/ol.2023.14119","volume":"26","author":"YL Zeng","year":"2023","unstructured":"Zeng, Y. L. et al. USF1 modulates transcription and cellular functions by regulating multiple transcription factors in Huh7 cells. Oncol. Lett. 26, 532 (2023).","journal-title":"Oncol. Lett."},{"key":"81642_CR57","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1111\/cas.16186","volume":"115","author":"Y Lai","year":"2024","unstructured":"Lai, Y. et al. EZH2 suppresses ferroptosis in hepatocellular carcinoma and reduces sorafenib sensitivity through epigenetic regulation of TFR2. Cancer Sci. 115, 2220\u20132234 (2024).","journal-title":"Cancer Sci."},{"key":"81642_CR58","doi-asserted-by":"publisher","first-page":"100741","DOI":"10.1016\/j.tranon.2020.01.002","volume":"13","author":"S Wang","year":"2020","unstructured":"Wang, S. et al. Inhibition of EZH2 attenuates Sorafenib Resistance by Targeting NOTCH1 activation-dependent Liver Cancer Stem cells via NOTCH1-Related MicroRNAs in Hepatocellular Carcinoma. Transl Oncol. 13, 100741 (2020).","journal-title":"Transl Oncol."},{"key":"81642_CR59","doi-asserted-by":"publisher","first-page":"215899","DOI":"10.1016\/j.canlet.2022.215899","volume":"548","author":"L Zhang","year":"2022","unstructured":"Zhang, L. et al. DNMT and EZH2 inhibitors synergize to activate therapeutic targets in hepatocellular carcinoma. Cancer Lett. 548, 215899 (2022).","journal-title":"Cancer Lett."},{"key":"81642_CR60","doi-asserted-by":"publisher","first-page":"277","DOI":"10.2217\/epi-2017-0118","volume":"10","author":"V Modhukur","year":"2018","unstructured":"Modhukur, V. et al. MethSurv: A web tool to perform multivariable survival analysis using DNA methylation data. Epigenomics 10, 277\u2013288 (2018).","journal-title":"Epigenomics"},{"key":"81642_CR61","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black, J. C., Van Rechem, C. & Whetstine, J. R. Histone lysine methylation dynamics: Establishment, regulation, and biological impact. Mol. Cell. 48, 491\u2013507 (2012).","journal-title":"Mol. Cell."},{"key":"81642_CR62","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: Protein-protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"81642_CR63","doi-asserted-by":"publisher","first-page":"P3","DOI":"10.1186\/gb-2003-4-5-p3","volume":"4","author":"G Dennis Jr","year":"2003","unstructured":"Dennis, G. Jr. et al. Database for annotation, visualization, and integrated discovery. Genome Biol. 4, P3 (2003).","journal-title":"Genome Biol."},{"key":"81642_CR64","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1158\/0008-5472.CAN-12-1370","volume":"72","author":"WC Reinhold","year":"2012","unstructured":"Reinhold, W. C. et al. CellMiner: A web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. Cancer Res. 72, 3499\u20133511 (2012).","journal-title":"Cancer Res."},{"key":"81642_CR65","doi-asserted-by":"publisher","first-page":"D955","DOI":"10.1093\/nar\/gks1111","volume":"41","author":"W Yang","year":"2013","unstructured":"Yang, W. et al. Genomics of drug sensitivity in cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 41, D955\u2013961 (2013).","journal-title":"Nucleic Acids Res."},{"key":"81642_CR66","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1038\/nature11003","volume":"483","author":"J Barretina","year":"2012","unstructured":"Barretina, J. et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 483, 603\u2013607 (2012).","journal-title":"Nature"},{"key":"81642_CR67","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak, K. J. & Schmittgen, T. D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25, 402\u2013408 (2001).","journal-title":"Methods"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81642-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81642-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,29]],"date-time":"2024-11-29T11:03:51Z","timestamp":1732878231000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-81642-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,29]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["81642"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-81642-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,29]]},"assertion":[{"value":"14 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was authorized by the Ethics Committee of Zhongda Hospital affiliated with Southeast University, China. Informed consent was obtained from all individual participants included in the study. All research involving humans was carried out in accordance with The Code of Ethics of the World Medical Association (Declaration of Helsinki).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"29695"}}